No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y 12 inhibitors were first demonstrated relative to clopidogrel.
F low restoration through an infarct-related artery via implantation of intracoronary stents during primary percutaneous coronary intervention (PCI) is, if possible, the preferred reperfusion therapy in patients with acute myocardial infarction (AMI) with ST-segment elevation (STEMI). 1 The highest thrombotic risk associated with this condition requires intensive antithrombotic treatment. 2 In addition to aspirin, guidelines recommend the use of ticagrelor or prasugrel over clopidogrel. 1, 3 Except for patients after an ischemic stroke, in whom prasugrel is contraindicated, class and level of guideline recommendations are identical for both agents. Physicians are increasingly being confronted with the need to select a P2Y 12 antagonist as part of the daily care of patients with AMI. For all practical purposes, there has been only 1 randomized trial that supports each of the newer P2Y 12 inhibitors (ie, prasugrel and ticagrelor) in the treatment of acute coronary syndromes instead of clopidogrel. 4, 5 However, the reported use of prasugrel and ticagrelor in routine clinical practice suggests that physicians do not view these agents as interchangeable and tend to favor one over the other for their patients. [6] [7] [8] [9] Economic constraints associated with treatments with newer medications are an important factor in the selection of a P2Y 12 inhibitor. In addition, the availability of low-cost generic clopidogrel must be taken into account. This factor frequently results in substituting the less costly clopidogrel for newer P2Y 12 inhibitors over the course of the recommended 12-month treatment interval in many healthcare systems.
The need for a head-to-head comparison of newer P2Y 12 inhibitors motivated us to perform the PRAGUE-18 study, which was a randomized, multicenter study designed to compare the efficacy and safety of prasugrel and ticagrelor in patients with AMI treated with primary or immediate PCI and to assess the percentages, reasons, and consequences of switching from new P2Y 12 inhibitors to clopidogrel after the acute phase. This article deals with 7-and 30-day outcomes and thus represents a direct comparison of prasugrel and ticagrelor during these time periods. A 1-year follow-up is ongoing and will be completed in May 2017.
MethOds
The multicenter, randomized PRAGUE-18 study, an open-label, phase IV, controlled, clinical trial, is an academic project with participation of 14 tertiary cardiology centers in the Czech Republic with 24/7 capability to perform primary PCI. The study was conducted with approval of the trial design and protocol by the Ethics Committee for Multicenter Clinical Trials, University Hospital Kralovske Vinohrady, Prague, Czech Republic, and the local ethics committees at each participating site. The study protocol has been registered under PRAGUE-18 (http://www. ClinicalTrials.gov; NCT02808767).
The study was designed by the principal investigators (Z.M. and P.W.) and commented on by steering committee members during the initial investigator meeting. Coordination was managed by the Cardiocenter of the Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady in Prague, Czech Republic. 10 The study was an independent project and was conducted without any support from the industry. Study investigators joined and participated on a voluntary basis, out of scientific enthusiasm, without any compensation. A team from the Institute of Biostatistics and Analyses of Masaryk University, Brno, Czech Republic, led by one of the coauthors, was involved in preparing the study (power calculation), in creating and administering the electronic database, and in the statistical analysis of results. Data from the study were recorded through electron case report forms and stored in a database system originally based on a modified version of the TrialDB system. The system was designed as a robust base for the collection of large amounts of data in clinical trials or clinical registries and was fully customized to the structure of the project.
Simple randomization with GraphPad scientific software was adopted for the study. The sealed envelope method was used for distribution of randomization codes. Anonymous patient data, using the patient's serial number in the database and a randomization number, were added to an electronic clinical Perspective
What is new?
• The multicenter randomized PRAGUE-18 study is the first head-to-head comparison of prasugrel and ticagrelor in acute myocardial infarction treated with primary or immediate percutaneous coronary intervention. • The study was designed as a superiority trial and was stopped prematurely because of futility after enrollment of 1230 patients. • The primary end point was defined as death, reinfarction, urgent target vessel revascularization, stroke, or serious bleeding requiring transfusion or prolonging hospitalization within 7 days after enrollment. The key secondary end point within 30 days was composed of cardiovascular death, nonfatal myocardial infarction, or stroke.
What are the clinical implications?
• The study does not support the hypothesis that one of the newer P2Y 12 inhibitors is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with primary or immediate percutaneous coronary intervention. The observed percentages of major outcomes were similar and with clinically irrelevant differences between the compared groups but with broad confidence intervals around the estimates. • A randomized study of a sufficient sample size and with an optimal design for an evaluation of equivalence remains a challenge for the comparison of prasugrel and ticagrelor.
database. Only the investigators had access to the data of participants enrolled at their respective sites during the course of the study. Proper conduct of the study at the participating sites was supervised by the associated executive and steering committees and by the data monitoring committee of the coordinating site. The data monitoring committee of the coordinating site monitored study progress at individual sites.
The incidence of outcome measures was verified by an independent committee, the members of which were not involved as study investigators and were not aware of the treatment assignments (see the Appendix in the online-only Data Supplement for committee members and study investigators).
The first author (Z.M.) had access to all study data (ie, the protocol, study approval by the ethics committees of the participating sites, informed consent forms of the randomized patients, and, after the database was locked, all entered data and patient source documentation with end points).
study Patients
Patients with AMI treated with a primary (more general term used for both STEMI and very-high-risk non-STEMI) PCI strategy were enrolled in the study. The study inclusion criteria were the following: AMI indicated for emergent (within 120 minutes of admission to a cardiac center) coronary angiography with or without PCI and a signed informed consent. Hemodynamic instability was not an exclusion criterion for study participation. A diagnosis of AMI was determined from the clinical presentation and an ECG finding of ST-segment elevation on 2 related leads at a minimum by >1 mm, ST-segment depression on 3 leads at a minimum by >2 mm, or a new bundlebranch block. Exclusion criteria for the study were history of stroke, serious bleeding within the past 6 months, indication for long-term oral anticoagulation therapy, administration of clopidogrel ≥300 mg or any other antiplatelet medication (except aspirin and a lower dose of clopidogrel) before randomization, aged >75 years with a body weight <60 kg (ie, the presence of both parameters was an exclusion criterion), moderate or severe hepatic function disorder, concomitant treatment with a strong CYP3A4 inhibitor, and known hypersensitivity to prasugrel or ticagrelor.
study design and treatment
The patients were randomized, after signing the informed consent, to prasugrel or ticagrelor therapy immediately on hospital arrival (which, as a rule, was directly to the catheterization laboratory or, in exceptional cases, to the coronary care unit). The dosing scheme for patients randomized to prasugrel was a 60-mg loading dose and 10 mg once daily as a maintenance dose. In patients aged >75 years of age or in those with a weight <60 kg, the maintenance dose of prasugrel was reduced to 5 mg once daily. Patients assigned to the study arm with ticagrelor received a loading dose of 180 mg and 90 mg twice daily as a maintenance dose.
Administration of the loading dose was recommended immediately after the patients signed the informed consent. In individual cases in which the physician could not exclude the need for urgent surgical revascularization on the basis of previous assessments or in cases involving hemodynamic instability, antiplatelet therapy was delayed until after coronary angiography and immediately before or shortly after PCI. In cases in which primary PCI was not performed, prasugrel therapy was discontinued and replaced by clopidogrel. The decision to perform the procedure and to administer any adjunctive medication to support PCI was left to the discretion of the treating physician.
Patients were advised to use the study medication for 12 months. Use of aspirin was also required with a recommendation of 100 mg daily.
Before discharge from the hospital, patients discussed with their physician the costs associated with the long-term therapy and the benefits of continued treatment with prasugrel and ticagrelor compared with clopidogrel. The study allowed patients who were unable to bear the costs associated with long-term treatment with the study medications to switch to clopidogrel because the latter is fully reimbursed by the state insurance company and poses no financial burden on patients.
Initial contact with the patient took place at the time of randomization, followed by visits on day 7 of hospitalization or at discharge if before day 7, on day 30 (telephone visit), and at 1 year from the index event.
study end Points
The primary composite end point consisted of all-cause death, reinfarction, stroke, serious bleeding requiring transfusion or prolonging hospitalization, or urgent target vessel revascularization within 7 days after randomization or at discharge if before the seventh day. Henceforth, the full definition is referred to as simply the primary end point. The key secondary efficacy end point was a composite of cardiovascular death, nonfatal myocardial infarction, or stroke during the follow-up period. Definitions of all study endpoints are presented in the Appendix in the online-only Data Supplement.
Additional secondary end points included definite stent thrombosis within 30 days from enrollment in the study. Academic Research Consortium criteria were used to define stent thrombosis. Bleeding occurrences defined according to the TIMI (Thrombolysis in Myocardial Infarction) and BARC (Bleeding Academic Research Consortium) criteria during the follow-up was a secondary safety end point. Another prespecified outcome measure was the occurrence of the primary end point in patients with Killip class III to IV and in those with diabetes mellitus.
statistical analysis
The power analysis was computed using Power and Precision software release 4.0 for a primary end-point difference of 2.5%, a 2-sided overall α level of 0.05, and statistical power of 80% (see the Appendix in the online-only Data Supplement for more details). The needed sample size was estimated at 1250 patients in each study arm. The interim analysis after the first 1130 patients led to a decision to terminate the study early because of futility. The differences in primary end point between study groups were plotted according to rank of recruitment; the difference between study groups was much below the expected clinically significant difference of 2.5%, which was used in the power analysis. Moreover, when real differences were compared with the borderline of minimal difference detected as statistically significant (ie, detectable alternative) for a given number of patients, they never cross.
We considered these results to be sufficient reason to end the study prematurely (see the Appendix in the online-only Data Supplement for more details).
Standard descriptive statistics were applied in the analysis: absolute and relative frequencies for categorical variables and medians supplemented with 5th and 95th percentiles for continuous variables. Statistical significance of differences among groups of patients was tested with the Fisher exact or χ 2 test for categorical variables and the Mann-Whitney test for continuous variables. Odds ratios (ORs), determined on the basis of logistic regression, were used to measure the effect of prasugrel versus ticagrelor with respect to the end points. The analysis was performed with SPSS 23.0.0.0 (IBM Corp).
resUlts study Population
In the period from April 2013 to May 2016, 1230 patients were enrolled in the study at 14 sites in the Czech Republic. The baseline characteristics of the patient set were balanced between the study groups, that is, nonstudy cardiovascular medication, time from the onset of symptoms to hospital admission, door-to-needle time, study drug-to-needle time, characteristics related to primary or immediate PCI, and periprocedural nonstudy antithrombotic therapy ( Table 1 and Table I in the online-only Data Supplement). Primary PCI was performed for STEMI or new bundle-branch blocks in both study arms in 94.6% of patients. Almost all patients (99.2%) enrolled in the study underwent primary PCI strategy; radial access was used in two thirds of the patients. At least 1 intracoronary stent was implanted in 96%, with drug-eluting stents used in 68.1% of all patients. An optimal postprocedural result with TIMI grade 3 flow in the infarct-related artery, assessed on-site by the experienced interventional cardiologist, was achieved in almost 95% of the patients.
Hemodynamic instability was not an exclusion criterion for study participation. Nearly 4% of patients in each group were in cardiogenic shock at baseline, and 5.2% were on mechanical ventilation.
Five patients failed to participate in the 30-day followup visit. However, information on vital status during the 30-day follow-up period was available for all study participants.
study end Points
The occurrence of the primary end point did not differ significantly between the groups receiving prasugrel and ticagrelor (4.0% and 4.1%, respectively; OR, 0.98; 95% confidence interval [CI], 0.55-1.73; P=0.939; Table 2 and Figure) . Furthermore, no significant difference was found in any of the components of the primary end point, that is, death, reinfarction, urgent target vessel revascularization, stroke, serious bleeding requiring transfusion, or prolonged hospitalization. The occurrence of key secondary end points within 30 days after randomization, composed of cardiovascular death, nonfatal myocardial infarction, or stroke, also did not show any significant difference between prasugrel and ticagrelor (2.7% and 2.5%, respectively; OR, 1.06; 95% CI, 0.53-2.15; P=0.864; Table 2 and Figure) . The results were also consistent for both the primary and key secondary end points across the analyzed subgroups of the whole study population ( Table  II in the online-only Data Supplement). There was no significant difference in the risk of the primary net clinical end point between prasugrel and ticagrelor in relation to age (aged ≥75 years; n=121; OR, 0.69; 95% CI, 0.19-2.48), presence of diabetes mellitus (n=251; OR, 0.86; 95% CI, 0.30-2.45), pre-PCI cardiogenic shock (n=45; OR, 0.79; 95% CI, 0.19-3.24), and pre-PCI Killip class higher than II (n=62; OR, 1.18; 95% CI, 0.33-4.26). No interactions were statistically significant.
Serious bleeding requiring transfusion or prolonging the hospital stay was a component of the net primary end point. Any bleeding unrelated to bypass surgery was recorded throughout the follow-up period. No significant difference was found between patients on prasugrel and ticagrelor according to TIMI and BARC bleeding events (Table 3 and Figure I in the online-only Data Supplement).
discUssiOn
Evidence from randomized studies comparing the benefits of prasugrel and ticagrelor in patients with STEMI treated with primary PCI is still lacking. Subgroup analyses of studies comparing the newer P2Y 12 inhibitors with clopidogrel provide only limited information on the population of patients who are treated with emergent primary PCI for STEMI. [11] [12] [13] Published landmark analyses of the TRITON (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel) and PLATO (Platelet Inhibition and Patient Outcomes) studies discussed the maximum effectiveness of ticagrelor and especially prasugrel in the acute phase of myocardial infarction, during the first 7 days in which the thrombotic risk is highest. 14, 15 According to the published data, the cumulative incidence of ischemic events differed between patients treated with ticagrelor and those treated with prasugrel during this phase of AMI. Documented differences were the basis for superiority design of the presented study in which a homogeneous (with respect to the highest thrombotic risk) patient population with STEMI was enrolled. The selected net primary end point reflects both important aspects of antiplatelet treatment: efficacy and safety. 16, 17 The observed occurrences of major efficacy and safety outcomes in the multicenter randomized PRAGUE-18 study comparing prasugrel and ticagrelor were similar but with broad confidence intervals around the estimates because of the small number of subjects. Compared with clopidogrel, the clinical benefit of these drugs is the re- Figure. cumulative Kaplan-Meier estimates of the percentages of the primary and key secondary end points.
ORIGINAL RESEARCH ARTICLE 1609 sult of their greater antiplatelet efficacy and its faster onset. 18, 19 Although the drugs differ in their mode of action on P2Y 12 receptors, the level of inhibition of platelet aggregation is quite similar. 7 Randomized study in patients with STEMI undergoing primary PCI have confirmed that neither of the new P2Y 12 inhibitors was superior to the other in laboratory antiplatelet efficacy. 20 Percentages of cardiovascular death, ischemic events, definite stent thrombosis, and bleeding events in subgroup analyses of patients with STEMI included in the TRITON-TIMI 38 study, which was designed to verify the benefit of prasugrel over clopidogrel, and PLATO study, which compared the benefit and risks of ticagrelor and clopidogrel, were essentially similar. 11, 12 However, comparisons of subgroup analyses of randomized trials whose designs and study populations differ are often prone to bias. A retrospective analysis of a large register comparing efficacy and safety of prasugrel and ticagrelor in patients undergoing PCI for acute coronary syndrome was limited by significant differences in the baseline characteristics of patients on prasugrel and those on ticagrelor. 6 After propensity matching, major adverse cardiovascular events, mortality, and major bleeding events associated with prasugrel were not inferior to the occurrence of events associated with ticagrelor.
The baseline characteristics of the PRAGUE-18 study population were well balanced between the compared groups and comparable to those in contemporary studies of patients with AMI who underwent primary PCI. [21] [22] [23] Patient mortality was low and is in accordance with rates reported in contemporary, published, randomized studies. Results of the presented study are consistent with the actual and reportedly changing trend in the prognosis of patients with STEMI treated with primary PCI, with the predominance of radial access (66.4%) and the use of drug-eluting stents supported by the most efficient available dual or triple (bailout therapy with a glycoprotein IIb/ IIIa inhibitor) antiplatelet therapy. A 30-day mortality of <3% in patients with radial access has also been demonstrated in a study in which patients with STEMI were treated with PCI and a 600-mg loading dose of clopidogrel. 22 There was a 30-day on-treatment cardiovascular mortality of 2.3% in a study in which newer P2Y 12 inhibitors were used for dual antiplatelet therapy in <30% of the study population of patients with STEMI treated with primary PCI and thrombectomy. 23 Patients with cardiogenic shock were excluded from the TRITON-TIMI 38 study. 5 In the PLATO study, <1% of the patients with STEMI enrolled were higher than Killip class II at baseline. 4 The Killip classification at admission was not an exclusion criterion for the PRAGUE-18 study. The incidence of the primary end point was 7 times higher for patients with cardiogenic shock compared with patients with Killip class I to III. The Killip classification did not influence the difference in the occurrence of primary end points between prasugrel-and ticagrelortreated patients. Our previous study documented strong and comparable antiplatelet efficacy for prasugrel and ticagrelor in the vast majority of patients with AMI after out-of-hospital cardiac arrest who were treated with mild therapeutic hypothermia. 24 Patients with cardiogenic shock are generally not included in randomized, clinical studies, and reported results on the efficacy and safety of the medications are very rare in this group of patients. Unfortunately, the results of the PRAGUE-18 study, given the small number of patients enrolled, cannot offer relevant arguments on the differences between benefits and risks of newer drugs for subgroups of patients.
Concerns about a higher risk of bleeding associated with prasugrel compared with ticagrelor are still being discussed. [6] [7] [8] [9] 25 Large, contemporary registry data show that prasugrel used according to recommendations is safe in patients undergoing PCI for STEMI. 26 The prasugrel dose was reduced during the maintenance phase of the PRAGUE-18 study in patients >75 years of age and in patients weighing <60 kg. The incidence of bleeding complications associated with the study medications was low in both treatment arms, and the differences in the percentages of serious bleeding events did not reach statistical significance. Real-world evidence from 12 European registries shows that there are no major differences between prasugrel and ticagrelor with regard to the incidence of bleeding in patients with STEMI. 9 On the basis of the results of the TRITON-TIMI 38 study, the use of prasugrel is generally not recommended for older patients or those with low body weight because prasugrel was not associated with a net clinical benefit in these sub-sets. 7 A subgroup analysis of PRAGUE-18 study showed that patients >75 years had a higher risk of primary net clinical end point compared with younger patients. Age >75 years, however, did not influence the difference between the incidence of primary end point between those treated with prasugrel and those treated with ticagrelor. Nevertheless, this finding should be viewed in the context of the previously discussed limitations of subgroup analyses.
This study has several limitations. It was an open-label study. However, all primary end-point events were adjudicated by an independent event adjudication committee that was unaware of treatment allocation. The study was underpowered to draw the final conclusion of a direct comparison of efficacy and safety of prasugrel and ticagrelor. The study was terminated prematurely because of futility. The difference between study groups was much below the expected clinically significant difference (2.5% absolute reduction; relative risk reduction, 39%), which was used in the power analysis, and the CIs for the estimation of the incidence of events were quite wide. However, identified differences in the occurrence of a primary end point between the compared groups were very low in absolute numbers and clinically irrelevant (0.1%; number needed to treat=1000). Depending on the order in which patients were included in the study, the difference of occurrence of the primary end point between treatment arms was consistently low, and with a growing number of patients, it became stabilized around this value (Figures II and III in the online-only Data Supplement).
The results of PRAGUE-18 study point to the suitability of the noninferiority study design comparing efficacy and safety of both drugs on a sufficiently large patient sample size. The execution of a randomized study with a population including many thousands of patients is extremely expensive. Therefore, we cannot expect the industry to fund a head-to-head trial as part of a postlicensing evaluation. 27 This is also supported by the fact that our purely academic study was the first study to compare both drugs since the publication of the results from the TRITON and PLATO studies 7 years ago. We therefore hope that, despite the limitations of the presented study, the results of the PRAGUE-18 study will contribute to clinical practice.
cOnclUsiOns
This head-to-head comparison of prasugrel and ticagrelor, based on a small number of patients and events, does not support the hypothesis that one is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with primary or immediate PCI. The observed percentages of major outcomes were similar, with clinically irrelevant differences between the compared groups but broad CIs around the estimates. A randomized study of a sufficient sample size and with an optimal design for ORIGINAL RESEARCH ARTICLE 1611 an evaluation of equivalence remains a challenge for the comparison of prasugrel and ticagrelor. acKnOWledgMents All authors assume responsibility for the accuracy and completeness of the reported data and analyses and for having conducted the study according to the approved protocol. The authors thank Thomas Secrest, a senior lecturer at the Third Faculty of Medicine of Charles University in Prague, for professional language editing.
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